Nothing Special   »   [go: up one dir, main page]

SG10201402723QA - Flavonoid hydrogel - Google Patents

Flavonoid hydrogel

Info

Publication number
SG10201402723QA
SG10201402723QA SG10201402723QA SG10201402723QA SG10201402723QA SG 10201402723Q A SG10201402723Q A SG 10201402723QA SG 10201402723Q A SG10201402723Q A SG 10201402723QA SG 10201402723Q A SG10201402723Q A SG 10201402723QA SG 10201402723Q A SG10201402723Q A SG 10201402723QA
Authority
SG
Singapore
Prior art keywords
flavonoid
hydrogel
flavonoid hydrogel
Prior art date
Application number
SG10201402723QA
Inventor
Motoichi Kurisawa
Fan Lee
Joo Eun Chung
Pui Yik Peggy Chan
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG10201402723QA publication Critical patent/SG10201402723QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738Cross-linked polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/02Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075Macromolecular gels
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02Oxygen as only ring hetero atoms
    • C12P17/06Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2397/00Characterised by the use of lignin-containing materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Obesity (AREA)
SG10201402723QA 2009-05-29 2010-05-17 Flavonoid hydrogel SG10201402723QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21333109P 2009-05-29 2009-05-29

Publications (1)

Publication Number Publication Date
SG10201402723QA true SG10201402723QA (en) 2014-10-30

Family

ID=43222961

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201402723QA SG10201402723QA (en) 2009-05-29 2010-05-17 Flavonoid hydrogel
SG2011088283A SG176286A1 (en) 2009-05-29 2010-05-17 Flavonoid hydrogel

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011088283A SG176286A1 (en) 2009-05-29 2010-05-17 Flavonoid hydrogel

Country Status (5)

Country Link
US (3) US8541016B2 (en)
EP (1) EP2435504B1 (en)
JP (2) JP5843758B2 (en)
SG (2) SG10201402723QA (en)
WO (1) WO2010138082A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2214715B1 (en) * 2007-10-23 2018-04-18 Agency For Science, Technology And Research Method of delivering an anti-cancer agent to a cell
US8734867B2 (en) 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
EP2435504B1 (en) 2009-05-29 2020-03-11 Agency For Science, Technology And Research Flavonoid hydrogel
EP2544768A4 (en) * 2010-03-11 2016-02-24 Agency Science Tech & Res Anti-cancer agent delivery vehicles capable of improved laoding
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US8722040B2 (en) * 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms
EP3011016B1 (en) * 2013-06-18 2019-08-07 Agency For Science, Technology And Research Method of culturing cancer stem cells
EP3041830B1 (en) * 2013-09-03 2023-10-25 Agency For Science, Technology And Research Polymer-flavonoid conjugates and hydrogels for biomedical applications
GB2518405A (en) * 2013-09-20 2015-03-25 Zeiss Carl Meditec Ag Composition comprising at least one viscoelastic polymer
WO2015070100A1 (en) 2013-11-08 2015-05-14 The Johns Hopkins University Oxygen-controllable and hypoxia-inducible hydrogels
US10004586B2 (en) 2014-08-27 2018-06-26 The Cleveland Clinic Foundation Biocompatible tissue graft
US12077645B2 (en) * 2018-04-02 2024-09-03 Optipharm Co., Ltd Alginate microcapsules for cell encapsulation and, manufacturing method therefor
KR102326127B1 (en) * 2019-06-27 2021-11-12 서울대학교산학협력단 Development of injectable tissue adhesive hydrogel based on polyphenol and its application
EP4069303A4 (en) * 2019-12-03 2023-11-29 The Schepens Eye Research Institute, Inc. Injectable hydrogels for cell delivery to the vitreous
CN113892643A (en) * 2021-09-23 2022-01-07 西北农林科技大学 Manufacturing method of edible sodium alginate/gelatin 3D gel scaffold adopting tea polyphenol coating and used for cell culture meat
CN114736254B (en) * 2022-03-30 2024-01-05 湖南大学 Natural flavonoid derivative medicine and preparation method and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630457B1 (en) 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
US6982298B2 (en) 2003-01-10 2006-01-03 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US7858080B2 (en) 2005-05-20 2010-12-28 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
CN101180319B (en) * 2005-05-20 2012-06-27 新加坡科技研究局 Aldehyde conjugated flavonoid preparations
JP4712505B2 (en) * 2005-09-30 2011-06-29 富士フイルム株式会社 Electronic endoscope device
EP1988938A4 (en) 2006-02-27 2011-09-28 Agency Science Tech & Res Curable bone cement
JP2007297360A (en) * 2006-05-08 2007-11-15 Ihara Suisan Kk Hydrogel, production method thereof and use thereof
JP4308230B2 (en) * 2006-07-21 2009-08-05 花王株式会社 Method for inhibiting catechin coloring
US20100008869A1 (en) * 2006-07-21 2010-01-14 Kao Corporation Method for preventing coloration of catechins and dentifrice composition
KR100968591B1 (en) * 2007-06-14 2010-07-08 한국과학기술연구원 Polyorganophosphazene hydrogels for drug delivery, preparation method thereof and use thereof
EP2214715B1 (en) * 2007-10-23 2018-04-18 Agency For Science, Technology And Research Method of delivering an anti-cancer agent to a cell
WO2009148405A1 (en) 2008-06-05 2009-12-10 Agency For Science, Technology And Research Formation of hydrogel in the presence of peroxidase and low concentration of hydrogen peroxide
US8287906B2 (en) 2008-05-06 2012-10-16 Agency For Science, Technology And Research Formation of hydrogel in the presence of peroxidase and low concentration of hydrogen peroxide
EP2435504B1 (en) 2009-05-29 2020-03-11 Agency For Science, Technology And Research Flavonoid hydrogel
EP2544768A4 (en) 2010-03-11 2016-02-24 Agency Science Tech & Res Anti-cancer agent delivery vehicles capable of improved laoding

Also Published As

Publication number Publication date
EP2435504A4 (en) 2015-12-02
US8541016B2 (en) 2013-09-24
JP6112576B2 (en) 2017-04-12
JP2016014025A (en) 2016-01-28
JP2012528150A (en) 2012-11-12
WO2010138082A1 (en) 2010-12-02
SG176286A1 (en) 2012-01-30
US20130338101A1 (en) 2013-12-19
EP2435504B1 (en) 2020-03-11
JP5843758B2 (en) 2016-01-13
US20150313869A1 (en) 2015-11-05
EP2435504A1 (en) 2012-04-04
US9034364B2 (en) 2015-05-19
US20120070433A1 (en) 2012-03-22
US9439886B2 (en) 2016-09-13

Similar Documents

Publication Publication Date Title
SG10201402723QA (en) Flavonoid hydrogel
DK3023438T3 (en) Anti-gitr-antistoffer
DK2457337T3 (en) Specialtilpasset impuls-burst
EP2462514A4 (en) Greenbooks
EP2515891A4 (en) 3-keto-n-propargyl-1-aminoindan
EP2438115A4 (en) Immuno-compatible hydrogel system
HK1146920A1 (en) Scissor
EP2519921A4 (en) Call-tracking
DK2464943T3 (en) Systemintegration
GB0900568D0 (en) Poymerisation
GB0900319D0 (en) Hydrocharger
EP2510125A4 (en) Hyperprimers
AU4925P (en) Bonscawi Scaevola aemula
AU4926P (en) Bonscalib Scaevola aemula
AU4924P (en) Bonscablue Scaevola aemula
AU4240P (en) Tuckerbox xTriticosecale
GB0916459D0 (en) Concept 36a
GB0903349D0 (en) Concept four
EG26256A (en) Oxyga
HU0900041D0 (en) Crinoline
GB0901126D0 (en) Eco-frame
GB0900674D0 (en) Concrete-shifter
GB0900395D0 (en) Kelpipe
GB0900367D0 (en) Shelta
GB0900362D0 (en) Hipestone